Tag Archives: Takeda

Shire's Takhzyro gets off to hot start, boosting immunology sales ahead of Takeda buyout

Critics of Takeda’s $ 62 billion Shire buyout and Shire’s own investors have fretted lately about the company’s standing in the hemophilia market. But immunology is a different story. In the third quarter, the unit continued to post “strong growth,” as Jefferies analyst David Steinberg put it in a Thursday note to clients, with revenues… Read More »